Nasdaq
$0.9853▼ 1.24%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.1MShares out 4.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 9.30Pre-market26.09.30 21:096-KKey event#●●●#●●●
NuCana plcBullish
NuCana has been granted a new composition-of-matter patent (EP 3683225) by the European Patent Office for its anti-cancer candidate NUC-7738. This addition brings the company's global patent portfolio for the candidate to over 85 issued patents, and the company confirmed that its current cash resources are sufficient to fund operations into 2029.…more
$0.9853-1.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.18Overnight26.08.14 09:17filed6-KKey event
NuCana plc
NuCana announced its financial results for the second quarter of 2026, confirming the completion of patient recruitment for the Phase 2 expansion study of NUC-7738 with final data expected later this year. The company reported cash and cash equivalents of 19.5 million GBP, which it expects to fund operations into 2029.…more
$0.9853-1.24%vs prev closeView filingShare - 9.18Overnight26.06.25 00:09filed4Ownership
NuCana plc
Insider Elliott M. Levy of NuCana plc filed a Form 4 report regarding changes in beneficial ownership of securities as of June 19, 2026. This filing serves as a standard disclosure of insider transaction activity.…more
$0.9853-1.24%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.30Pre-market26.09.30 21:03#●●●#●●●#●●●
NuCana Secures European Patent for NUC-7738
NuCana has been granted a European patent for the composition of matter of its anti-cancer agent, NUC-7738. This milestone strengthens the company's global intellectual property strategy and long-term commercial protection for the drug.…more
$0.9853-1.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.28After-hours26.08.29 05:00
●●●●●●●● ●●●●● ●●●●●●
NuCana has been granted a European patent for its novel anti-cancer compounds. While this secures intellectual property rights for drug development, the impact remains neutral as no commercial or clinical milestones were announced.…more
$0.9853-1.24%vs prev closeShareBenzinga - 8.13After-hours26.08.14 05:01
●●●●●●●● ●●●●● ●●●●●●
NuCana announced the completion of patient recruitment for its Phase 2 study of NUC-7738, marking significant progress in its clinical development. The company maintains a strong financial position with sufficient cash runway to fund operations through 2029.…more
$0.9853-1.24%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report